Angiogenesis patch trial moves forward:
This article was originally published in Clinica
Advanced Tissue Sciences has begun a pivotal preclinical trial of its tissue-engineered epicardial patch for stimulating new blood vessel growth and improving the function of damaged heart tissue. The trial will assess the safety of the patch, called Anginera, in large animals. A previous study in mice has shown that the patch can improve overall function in damaged heart tissue without adversely effecting normal heart tissue function. Studies in large animals are required by the US FDA before starting human trials, noted the La Jolla, California firm. An efficacy trial in large animals is to begin this summer.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.